Comparative Analysis of 2 Diagnostic Devices for Detection of Mycobacterium tuberculosis and Drug Resistance in Almaty, Kazakhstan, to Determine the Optimal Diagnostic for Local Needs
Bartels J.G.E. Takenov N. Chingissova L. Rakisheva A. Eleusizova A. Bismilda V. Yeraliyeva L. Ben Amor Y.
1 July 2025Oxford University Press
Open Forum Infectious Diseases
2025#12Issue 7
Background Rapid, accurate detection of Mycobacterium tuberculosis and drug resistance is crucial to reduce tuberculosis (TB) burden and prevent development of drug resistance in high-burden drug-resistant TB regions. Methods From December 2021 to July 2022, sputum samples from 1214 adult patients with presumptive TB in Almaty, Kazakhstan, were tested by BD MAX MDR-TB (Becton Dickinson), Cepheid Xpert MTB/RIF, and mycobacterial growth indicator tube (MGIT) liquid culture for detection of TB and drug resistance to rifampicin (RIF) and isoniazid (INH). Results When compared with MGIT, BD MAX sensitivity and specificity for TB detection were 90% and 87%, and Xpert MTB/RIF results were 86% and 92%. For RIF resistance, BD MAX sensitivity and specificity were 91% and 95%, and Xpert MTB/RIF results were 94% and 92%. For INH resistance, BD MAX sensitivity and specificity were 98% and 97%. Whole genome sequencing was conducted for 24 samples with discordant RIF resistance results among the 3 devices to determine mutations related to resistance. When compared with a composite standard based on whole genome sequencing and MGIT, Xpert MTB/RIF had higher sensitivity and specificity for RIF resistance than BD MAX. Conclusions Countries with high burden of drug-resistant TB should carry out national prevalence surveys to assess rates of multidrug-resistant TB and INH monoresistance. Those with higher rates should consider adopting BD MAX due to its ability to accurately diagnose RIF and INH resistance.
BD MAX , MDR , tuberculosis , whole genome sequencing , Xpert MTB/RIF
Text of the article Перейти на текст статьи
Center for Sustainable Development, Columbia University, New York, NY, United States
National Tuberculosis Reference Laboratory, National Scientific Center of Phthisiopulmonology, Almaty, Kazakhstan
Center of Phthisiopulmonology Almaty, Almaty, Kazakhstan
Center for Sustainable Development
National Tuberculosis Reference Laboratory
Center of Phthisiopulmonology Almaty
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026